Category Archives: Psoriasis

The stock price of MoonLake Immunotherapeutics (NASDAQ: MLTX) increased by 4.63% today. Investors are responding positively to a bullish research report.

H.C. Wainwright analyst Raghuram Selvaraju had initiated coverage on Moonlake Immunotherapeutics with a Buy rating. And Selvaraju assigned the company a price target of $28.

In our view, MoonLake possesses a possibly best-in-class agent in the IL-17-blocking category with sonelokimab (SLK), a novel nanobody targeting both IL-17A and IL-17F. SLK was originally developed by Ablynx N.V., a pioneer in the field of nanobodiesvery small antibody molecules using the features of the llama (camelid) antibody-generating systemthat was acquired by Sanofi S.A. in 2018 for 3.9 billion, wrote Selvaraju in a research note. MoonLake obtained the rights to SLK through a licensing agreement with Merck KGaA, which had in-licensed the molecule from Ablynx in 2013. From our vantage point, MoonLake benefits from the pedigree of SLK, which Merck regarded highly but that did not fit into its focus on oncology, neurology, fertility and endocrinology. In a Phase 2 trial published in The Lancet, up to 57% of patients with moderate to severe psoriasis who took SLK achieved clear skin (PASI 100) at week 24 and sustained responses over 52 weeks. There was also a numerical benefit over a Cosentyx (secukinumab) control arm and a favorable safety profile.

Plus Selvaraju believes that originally could be favorably positioned in psoriasis and psoriatic arthritis (PsA) compared to existing antibody drugs, which do not address blockade of all pathological forms of IL-17 and that have various off-target side effects. And Selvaraju noted that MoonLake is pursuing the development of sonelokimab in hidradenitis suppurativa (HS), a debilitating inflammatory skin disease for which there are currently no approved therapies.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

More:
MoonLake Immunotherapeutics (MLTX) Stock: Why It Increased 4.63% Today - Pulse 2.0

ALBANY, N.Y., June 24, 2022 /PRNewswire/ -- The psoriasis treatment market outlook by Transparency Market Research (TMR) expects the global market to expand at a CAGR of 8.7% during the forecast period, 2022-2031.

The study provides exhaustive analysis of factors impacting the market growth including ongoing trends of the psoriasis treatment market. This aside, it sheds light on the psoriasis treatment market statistics, which include revenues, sales, volume, and shares of the market.

Among different drug class, players in the psoriasis treatment market are expected to observe continue growth in the demand for interleukin inhibitors during the forecast period. This growth is ascribed to factors such as advanced safety and effectiveness of drugs in this class for the psoriasis treatment. Increase in the adoption of this drug class is attributed to interleukin blockers, which are known as an effective option for individuals whose body doesn't show response to other treatment solutions, notes a TMR analysis on the global psoriasis treatment market.

Request Brochure of Psoriasis Treatment Market Research Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17960

Psoriasis Treatment Market: Key Findings

Request for Analysis of COVID-19 Impact on Psoriasis Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=17960

Psoriasis Treatment Market: Growth Boosters

Get Exclusive PDF Sample Copy of Psoriasis Treatment Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

Psoriasis Treatment Market: Regional Analysis

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=17960

Psoriasis Treatment Market: Key Players

Some of the key players profiled in the report are:

Psoriasis Treatment Market Segmentation

Drug Class

Route of Administration

Distribution Channel

Regions Covered

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated withLatest Healthcare Industry Research Reportsby Transparency Market Research:

TNF Inhibitors Market: The rise in global occurrence of autoimmune illnesses such as Psoriasis, Inflammatory Bowel Disorder, Rheumatoid Arthritis (RA), and Crohn's disease, as well as the rise in the elderly populace, are the primary reasons likely to drive the expansion of the global TNF inhibitors market.

Vitamin D Testing Market: Rise in the prevalence of vitamin D deficiency and the surging focus on its importance contribute to the increase in screening for vitamin D serum levels, which, in turn, boosts the growth of the global vitamin D testing market.

Vitamin Deficiency Treatment Market: Rise in global geriatric population and high demand for Vitamin D and Vitamin B complex due to numerous health benefits are projected to drive the global vitamin deficiency treatment market.

Acute Exacerbation of CRS Treatment Market: Acute Exacerbation of CRS Treatment Market is driven by rise in mucosal inflammation incidences leading to rhinosinusitis is expected to drive the demand for acute CRS exacerbation treatment over the next few years.

Amblyopia Treatment Market: Amblyopia treatment market is driven by rise in prevalence of amblyopia and launch of technologically advanced products are projected to drive the global amblyopia treatment market.

Varicose Veins Treatment Market: Global varicose veins treatment market is driven by the rise in prevalence of varicose veins. Recent improvements in varicose veins treatment devices, such as compression therapy devices or ablation devices, has led to an increase in demand for these devices.

Glioblastoma Multiforme Treatment (GBM) Market: The rise in prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes is expected to drive the glioblastoma multiforme (GBM) treatment market.

Recto-vaginal Fistula Treatment Market: Rise in prevalence of Crohn's disease leading to the occurrence of recto-vaginal fistula drives the global recto-vaginal fistula treatment market.

About Us

Transparency Market Research is a global market intelligence company providing syndicated research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact Us:Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:http://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:sales@transparencymarketresearch.com

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

SOURCE Transparency Market Research

View post:
Psoriasis Treatment Market Players Observe Rising Trend of Personalized Medicines, According to TMR Report - PR Newswire UK

There are a number of different types of psoriasis, which can vary in their severity, location on the body, and physical appearance.

Fortunately, there are many treatments available that can help.

Psoriasis is a skin condition that causes skin cells to form too quickly.

Because these grow faster than the body can shed existing skin cells, thick, scaly patches form.

On lighter skin tones, this condition usually appears as pink or red patches with silvery-white scales.

On darker skin, psoriasis is more likely to appear as purple patches with gray scales or as a dark brown color.

Types of the condition include:

People with this condition may initially only develop one type, but can develop another type at a later point in time.

While a persons symptoms will vary with the type they have, most people will experience some combination of:

This means that they may increase in intensity at certain periods and lessen at others.

People refer to these periods of heightened symptoms as flares.

Flares can vary in severity and duration.

This type, also known as psoriasis vulgaris, causes areas of plaque buildup on the skin and is the most common form of condition.

Around 80-90% of people with this condition develop plaque psoriasis.

Plaque is a thickened area of skin.

On lighter skin types, it often has a white or silvery, scaled appearance, and on darker skin types it may appear as purple patches with gray scales.

Plaque psoriasis tends to be mild to moderate but can be severe.

Typically, mild plaque psoriasis covers less than 3% of the body, moderate plaque psoriasis 3-10%, and severe cases cover 10% or more.

These symptoms can include:

Areas of plaque may appear anywhere on the body but are most common on the knees and elbows.

Treatment of mild or moderate type will vary depending on a persons individual symptoms.

However, treatment will typically include the application of topical ointments to affected areas, and in some cases exposing the skin to ultraviolet light.

This type typically occurs on a persons scalp.

However, it can also appear on the forehead, back of the head, down the neck, and behind the ears.

This is common among people with psoriasis.

A person with scalp psoriasis can have other types on other parts of their body at the same time.

Treatment often involves more than one method at a time.

As with plaque psoriasis, a doctor will tailor a treatment program to a patients needs.

Treatment options include:

Learn more about the best shampoos for psoriasis here.

Guttate is characterized by red, purple, or dark dots and spots spread throughout the skin.

The dots and spots are not as thick as plaques in plaque psoriasis.

This type often starts in childhood or young adulthood and appears after an infection.

This type typically causes spots to appear on the legs, arm, and torso.

However, these may also appear on the face, scalp, and ears.

In severe cases, there may be hundreds of these spots, and they may cover the majority of an affected area.

Doctors will typically recommend topical creams and ointments as the first step for treating guttate psoriasis.

These treatments may help reduce swelling and alleviate itching.

As the condition can appear following infections such as strep throat, a doctor may recommend antibiotics to treat the infection alongside addressing the psoriasis symptoms.

In some cases, they may also suggest a patient undergo light therapy.

This type appears as patches of discoloration that are most often found in the folds of the skin, such as in the armpits and groin.

People with the inverse type often have other forms of psoriasis elsewhere on their bodies.

On white skin, this condition presents as bright red or pink marks.

On black or brown skin it may appear as red, purple, or darker than the surrounding area.

Areas of the body that are most likely to be affected include:

The areas of the body that are most often affected by inverse psoriasis tend to have thinner skin than other areas.

This can make treating this type more difficult.

A doctor will typically recommend topical steroid ointments to reduce inflammation.

As skin folds are common sites of yeast infection, they may also suggest a person take anti-yeast and anti-fungal treatments as well.

This is a severe, rare type of psoriasis.

It causes widespread inflammation of the skin and white or yellow blisters that contain pus.

Pustular psoriasis blisters can be limited to one area of the body or appear more generally.

Once the blisters have gone away, the skin may become scaly.

A person may also experience:

A specific kind of this type called palmoplantar pustulosis causes blisters to form on the palms and soles of the feet.

These blisters form in a studded pattern.

Over time, the blisters turn brown and become crusty.

Due to the rarity of the condition, there is a lack of evidence-based treatment guidelines.

As a result, medical professionals may recommend a combination of topical ointments, oral medications, and therapies.

They may also cycle between medications and therapies to find the most effective option and reduce the risk of side effects.

A person with mild pustular psoriasis may be able to treat the condition with prescription topical ointments.

However, those with more extensive symptoms may require hospital treatment.

While most forms of psoriasis tend to be mild or moderate, erythrodermic psoriasis is severe and can be a life-threatening medical emergency.

This type covers 80-90% of the body.

It causes an extremely painful, peeling rash that looks like a burn.

Unlike symptoms of the types of mild type, symptoms of erythrodermic psoriasis tend to be serious.

They may include:

People who have this type are prone to infection.

They may also experience other serious problems, including heart failure and pneumonia.

People with this condition are often hospitalized and may require emergency treatment.

This may include fluid replacement and systemic medications, which affect the whole body.

Depending on the severity of the condition, a medical professional may recommend oral retinoids, which are medicines derived from Vitamin A that can slow skin cell growth and reduce swelling, and immunosuppressive drugs, which reduce the bodys immune system response.

Biologic therapy is also a potential course of treatment.

Biologics target cytokines, which are signaling molecules that assist in the movement of cells to sites of inflammation.

By suppressing or inhibiting these signals, biologics can reduce the severity of inflammation.

In mild cases, focused treatment for the symptoms may include topical steroid creams and ointments, wet dressings, and oatmeal baths.

Most types of ps. tend to be of mild to moderate severity.

This exception is erythrodermic ps., which can be a life-threatening medical emergency.

However, if a person has moderate to severe symptoms a doctor may prescribe new biologic therapies.

These can help treat the underlying cause of skin changes and may reduce the number of flares and severity of symptoms.

People who suspect that they have p. should consult their doctor before beginning treatment.

People with symptoms of erythrodermic ps. should seek immediate medical attention.

Emergency Live Even MoreLive: Download The New Free App Of Your Newspaper For IOS And Android

Epidermolysis Bullosa And Skin Cancers: Diagnosis And Treatment

SkinNeutrAll: Checkmate For Skin-Damaging And Flammable Substances

Healing Wounds And Perfusion Oximeter, New Skin-Like Sensor Can Map Blood-Oxygen Levels

Psoriasis, An Ageless Skin Disease

Psoriasis: It Gets Worse In Winter, But Its Not Just The Cold Thats To Blame

Childhood Psoriasis: What It Is, What The Symptoms Are And How To Treat It

Topical Treatments For Psoriasis: Recommended Over-The-Counter And Prescription Options

Medical News Today

Follow this link:
What are the different types of psoriasis? - Emergency Live International

Psoriatic arthritis is a type of arthritis that affects about 20 to 30 percent of people with the autoimmune condition psoriasis. It develops when your immune system attacks healthy cells in your joints, leading to symptoms like joint pain, stiffness, or swelling.

For some people, symptoms can be severe enough to cause permanent disability.

Psoriasis and psoriatic arthritis can have many complications caused by inflammation throughout your body. Inflammation in your inner ear can cause dizziness or vertigo. Some medications used to treat psoriasis can also lead to these side effects.

Read on to learn more about the connection between psoriatic arthritis, dizziness, and vertigo.

Psoriasis and psoriatic arthritis raise levels of pro-inflammatory molecules called cytokines throughout your body. Elevated levels of these molecules lead to chronic inflammation that can raise your risk of many seemingly unrelated conditions, like:

Vertigo and dizziness are also potential complications of psoriatic arthritis. They develop mainly because of an atypical immune response directed against cells in your inner ear.

When your immune system attacks these cells, it can lead to inflammation and dysfunction of your vestibular system. Your vestibular system is a series of bony labyrinths in your inner ear that helps regulate your sense of balance.

In a small 2017 study, researchers found evidence that people with psoriatic arthritis had a higher frequency of vestibular dysfunction than the general population.

Among 60 people with psoriatic arthritis and 60 controls, one-third of people with psoriatic arthritis had vestibular dysfunction compared with only 6 percent of people in the control group.

Psoriasis is often treated with drugs like TNF-alphas inhibitors, T-lymphocyte inhibitors, and interleukin inhibitors. Some of the medications used to treat psoriasis, like the following, can potentially cause dizziness as a side effect:

Vertigo is often confused with dizziness. The two conditions are similar but not the same.

Vertigo is the feeling the world is spinning in the absence of movement. Dizziness is a more general term that refers to the feeling that you or your surroundings are moving when theyre not.

Inflammation in your inner ear associated with psoriatic arthritis can also potentially contribute to the development of vertigo.

In the 2017 study, researchers found that two people with psoriatic arthritis had vertigo, versus no one in the control group.

Treating psoriatic arthritis may help reduce associated inflammation and help ease dizziness or vertigo. Treatment for psoriatic arthritis focuses on:

The main medications for psoriatic arthritis include:

Vestibular rehabilitation is an exercise program that may help reduce dizziness or vertigo. Research has found that it can be effective for treating symptoms of many inner ear disorders. Its usually performed by a physical or occupational therapist with specialized training.

Psoriatic arthritis primarily affects the joints in your fingers, wrists, ankles, or knees. Symptoms can include:

Some people also experience symptoms that affect their nails. They can include:

If psoriatic arthritis isnt treated properly, you can develop other health problems like:

Its generally a good idea to visit a doctor any time you have dizziness or vertigo without a known cause.

Its important to seek immediate emergency medical attention if you also have symptoms that can indicate a medical emergency, like:

Most people who develop psoriatic arthritis already have a diagnosis of psoriasis. Regular follow-ups with your doctor are an important part of treating psoriasis. Its a good idea to visit your doctor if:

Dizziness and vertigo are potential side effects of psoriatic arthritis.

They can develop due to inflammation in the part of your inner ear that controls your balance called your vestibular system. Some medications used to treat psoriatic arthritis can also potentially cause these symptoms.

If you have psoriasis or psoriatic arthritis, its important to visit a doctor any time you notice new symptoms. A doctor can help you rule out other causes of these new symptoms and help you develop the best treatment plan.

Follow this link:
Psoriatic Arthritis and Dizzy Spells: The Connection, Treatment - Healthline

A Food and Drug Administration (FDA) approval for a highly anticipated treatment is the kind of news that can make a company's stock skyrocket, even during a bear market -- like the one we're in now.

One company hoping for such success is Arcutis Biotherapeutics (ARQT -6.91%). It has been developing a treatment for Seborrheic dermatitis -- a skin disorder that causes scaly skin, or dandruff-like flakes, on the face and scalp. It affects 7% of the global population. There are treatments on the market, but none has been developed that can clear it up for good. So companies that develop a successful way to fight the disease have a promising opportunity.

Arcutis is awaiting the outcome of an FDA review that would expand its customer base and boost revenue. Should investors be as equally excited? Let's take a closer look.

In September, I provided readers with an article discussing a pending FDA approval for a therapy from Arcutis that treats psoriasis. The company is now using a similarly based approach to treating dermatitis. That, together with $225 million in newly secured debt financing, could help 2023 be a huge year for the company.

After the FDA accepted its application in December, Arcutis received a path to that needed financing by way of SLR Capital Partners, which is providing $75 million upon closing of the loan facility with the potential for another $125 million upon FDA approval of its current drug, roflumilast. The final $25 million would be achievable as Arcutis hits certain revenue milestones.

With top treatments like Otezla already on the market from big names like Amgen, Arcutis could benefit from offering a deeper pipeline that reaches more potential customers. And so the company is also developing a foam version of roflumilast -- which should please investors.

With the funding in place, Arcutis is closing in on the July 29 PDUFA date, which is when the company can expect the FDA's response to its submission. Arcutis hopes it will bring FDA approval to its roflumilast cream to treat plaque psoriasis -- a projected $47 billion market by 2029, growing at a compound annual rate of 9%.

The cream form of roflumilast to treat psoriasis could be worth $1 billion in annual revenue. In trials, it achieved favorable efficacy against Otezla. Based on its non-steroidal form, it's expected to be offered at a lower price than the oral Otezla, and could likely come with less side effects such as nausea, headaches, and diarrhea reported by 20% of Otezla patients.

Now, Arcutis is furthering its development of roflumilast to incorporate a foam form of the treatment in order to serve those who suffer from seborrheic dermatitis, which impacts the face and scalp. In phase 3 clinical trials, the treatment achieved an 80% success rate compared to 59% in the control group receiving a placebo treatment, with improvement showing as early as the second week of treatment. The company also achieved success when it comes to variables related to itching, scaling, and redness -- 66% success versus 42% of those on a placebo.

Based on feedback from the FDA, Arcutis has high hopes for eventual approval, with no limiting safety warnings attached to the final product. The company believes the study results are sufficient to support approval, and intends to file with the FDA in the first half of 2023. If approved for seborrheic dermatitis and atopic dermatitis, that could introduce Arcutis to an additional market value of $27 billion over the next five to seven years, in addition to the $47 billion from plaque psoriasis.

Investors will be looking toward that July 29 PDUFA date for word from the FDA related to plaque psoriasis. In the meantime, investors who are more risk-tolerant could consider buying shares prior to the news. Analysts from Cowenand Mizuho believe peak sales for an approved roflumilast for treatment of psoriasis could hit $1 billion, with Mizuho analyst Uy Ear saying the treatment has blockbuster potential.

Arcutis' stock price has gone from a high of $36 in February 2021, when clinical trials showed promise for roflumilast in treating psoriasis, to a low of $14 this past January due to market volatility and its lack of FDA approval. Now, news of additional trial success and a nearing PDUFA date may be just what the doctor ordered for investors.

The company has funds to support development, along with promising data, and analysts believe the stock price could rise 125%.It could be that the only thing holding the stock back right now is the uncertainty of the broader market, but when you look into the potential for Arcutis, it could be a diamond in the rough for investors.

Continued here:
Could 2023 Be a Breakout Year for This Pharma Stock? - The Motley Fool

An influencer who has gone viral thanks to her honesty about her psoriasis has decided to stop receiving treatment.

Claire Spurgin, a junior sommelier from Sussex, spent years covering her red flaky patches of skin out of fear people would make fun of her.

But now aged 25, Claire bravely shares snaps of her body as she refuses to hide from the world any longer.

READ MORE: Woman, 25, covered in psoriasis bravely bares body - 'I refuse to hide any more'

The content creator decided to stop the treatment she was on as it wasnt working.

This means she has to wait a while before she can start another, which resulted in a flare-up.

She regularly updates her followers with the progress of her skin, with one caption reading: I think this is how my skin is now.

My skin flared so much after I stopped treatment but deep down I knew my psoriasis would calm and I just had to get myself through that flare.

Something I didnt talk about was the fact I couldnt go to work for two days because of my psoriasis.

My skin was so sore and I was just too emotional. It's now been two months since I stopped Ciclosporin and my psoriasis may be extremely visible but it doesnt hurt and thats all I ever wanted!

Claire, from Essex, has also opened up about how psoriasis and mental health issues often come hand in hand.

Her honesty has helped educate people about various skin conditions.

When my psoriasis started in 2016 I didnt see light at the end of the tunnel. My skin condition consumed me and its all I could focus on, she explained.

I hated my reflection in the mirror and I lost all confidence. It took years until I was able to say the words I have psoriasis.

My mindset is the complete opposite now and if I can overcome how I felt at 19, then I can do anything!

Its not easy to accept such a change in your appearance but when you realise youre unique, it becomes easier to show your skin.

The influencer said that every skin day is unpredictable and lifestyle choices have a huge effect on her skin.

Unfortunately due to Claires inconsistent working hours in hospitality, it is hard her for to have a consistent routine.

My psoriasis is always changing, some days are oddly calm and other days were flaring out of nowhere, she shared.

For me, there is no telling what my skin will do next and I think thats because every day in life is so different. Lifestyle has a huge effect on our skin.

My routine is always changing and with that so are my emotions. Working hospitality my hours and eating habits have no structure and living in the UK the weather is so diverse.

To stay up to date with all the latest news, make sure you sign up for one of our newsletters here.

Claire said that sometimes you feel like youre in control of your disease and other times you may sink into despair, which is okay.

She added: Its an emotional rollercoaster and its teaching us. We learn and we become stronger but it also humbles us.

The 25-year-olds honesty and openness has helped her grow her Instagram account, which currently has 44,000 followers.

They regularly share their support on her photos.

Still stunning and so brave for sharing your journey with us all, one person wrote.

My beautiful warrior Queen! Stay strong ik [sic] youll find a treatment that will help with your flare-ups, stay positive my love! said another.

A third added: Bless you! Still soooo beautiful!

READ NEXT:

Go here to read the rest:
Woman covered in psoriasis refuses to hide and can finally look in the mirror - Daily Star

Among a real-world cohort of patients, switching between infliximab biosimilars was effective and well tolerated, although retention was higher among those who had initially started on the originator product.

While providers are becoming more familiar with the idea of switching patients from reference biologics to biosimilars, it is less common to switch from one biosimilar to another. However, nonmedical switching among biosimilars may occur to save costs.

A study of more than 1500 patients in a real-world setting found switching between infliximab biosimilars was effective and well tolerated. The findings were presented at EULAR 2022, the annual meeting of the European Alliance of Associations for Rheumatology.

The observational cohort study was based on the DANBIO registry and investigated the effectiveness of switching patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) from CT-P13 to GP1111. The study included patients who had been switched from the originator to CT-P13 and patients who had never received the originator product.

Patients were included if they had experienced a biosimilar-to-biosimilar switch between April 1, 2019, and February 1, 2020. The main outcomes were treatment retention on GP1111 after 1 year and changes in disease activity from the 4 months prior to the switch compared with the 4 months after the switch.

The study included 1171 patients who were originator nave and 434 who had already switched from the originator. Among the full population, 685 had RA, 314 had PsA, and 606 had AxSpA. The median disease duration was 9 years. Slightly less than half (42%) were in remission at the time of the switch, according to the Disease Activity Score 28-joint count or Ankylosing Spondylitis Disease Activity Score.

Patients who had been on the originator product had a greater 1-year retention. One year after the switch, 83% (95% CI, 81%-85%) of patients who had never been on the originator maintained GP1111 treatment compared with 92% (95% CI, 90%-95%) of those who had initially switched from the originator. Among patients with RA and PsA, the risk of GP1111 withdrawal was lower among those who had been on the originator; however, there was no significant difference among patients with AxSpA.

For both groups, changes in disease activity were close to zero when comparing the 4 months prior with the 4 months after the switch. Lower disease activity at baseline was associated with higher retention across all 3 disease states. Having 1 or more comorbidities at baseline was also associated with a higher retention of GP1111 at 1 year.

According to the researchers, the difference in retention between the 2 groups suggests retention to be more affected by patient-related than drug-related factors. Overall, the biosimilar-to-biosimilar switch was effective and well tolerated.

According to The Center for Biosimilars, switching among biosimilars was becoming increasingly common in 2019, particularly in countries that utilize tenders for medicines and may ask patients to transition based on the outcomes of tenders.

In 2019, studies presented at United European Gastroenterology Week 2019 and the 6th Congress of Skin Inflammation and Psoriasis International Network had similarly supported the safety and efficacy of multiple biosimilar switching.

References

Nabi H, Hetland ML, Loft AG, et al. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic diseases: clinical outcomes in real-world patients from the DANBIO registry. Presented at: EULAR 2022; June 1-4, 2022; Copenhagen, Denmark. Abstract OP0065.

Read more:
Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds - AJMC.com Managed Markets Network

Doctor Robert Willan was the first to accurately describe the different types of psoriasis in the early 1800s. In the early 1960s, experts found that psoriasis was an autoimmune disorder, and modern treatment began in the mid-1900s.

In 1809, the English doctor Robert Willan was the first to develop an accurate description of the different types of psoriasis. While doctors learned more about the condition over the years, a pivotal finding emerged in 1963, when E. J. Van Scott found that psoriasis was an autoimmune disorder.

Modern treatment for this condition became available in the mid-1900s, and doctors still use these treatments today. Options include ultraviolet light and medications to reduce inflammation and suppress the immune system.

This article discusses the history and discovery of psoriasis and how treatment has changed.

According to the Psoriasis and Psoriatic Arthritis Alliance, people were aware of psoriasis as early as ancient Greece. Hippocrates wrote some of the first descriptions of skin conditions. However, he classified psoriasis in the same category as leprosy (Hansens disease).

People continued to classify psoriasis in the same category as Hansens disease for several centuries, and as a result, people with psoriasis often experienced stigma and were outcasts from society.

During the Renaissance period, several people wrote books further categorizing skin conditions. Two Italian authors, Girolamo Mercuriale and Bernardino Ramazzini, began to describe different skin conditions, including psoriasis, in their books De Morbius Cutaneis and De Morbis Artificum.

In 1809, the English doctor Robert Willan also categorized skin conditions. He was the first person to provide a description of different types of psoriasis, and he wrote about the progression of the condition.

While Robert Willan was the first person to investigate psoriasis as a separate condition, he still used the term lepra vulgaris, which contributed to people associating psoriasis with leprosy.

In the 1800s, the Austrian physician Ferdinand von Hebra was the first to use modern research techniques to study skin conditions. He also removed lepra from the description of psoriasis.

During this century, French doctors discovered the connection between psoriasis and a form of arthritis called psoriatic arthritis.

Other medical professionals of the time continued to make discoveries that led to later research subcategorizing psoriasis. For example, Australian dermatologist William J. Munro discovered mico-abscesses in the top layer of the skin in people with this condition. Later research would find that these abscesses are part of psoriasis vulgaris, a common form of this condition.

Heinrich Kbner made an important discovery during the 19th century. He found that people with psoriasis may also develop psoriatic lesions in previously unaffected areas that have experienced trauma, such as a cut, burn, or bruise. Doctors still use the Kbner phenomenon as a diagnostic tool today.

The 20th century saw various advancements in the classification of psoriasis and its symptoms.

In 1910, Leo von Zumbusch was the first to describe pustular psoriasis, a rare type of psoriasis that causes pustules, blisters, fever, and fatigue.

In 1926, Dr. Woronoff discovered that people with psoriasis may have a pale ring of skin around healing lesions. This halo, or Woronoff ring, is another diagnostic tool that medical professionals use. The appearance of a Woronoff ring may be a sign that psoriasis lesions are healing.

In 1963, E. J. Van Scott found that people with psoriasis have a rapid turnover of cells, which is a marker of an autoimmune condition. This discovery that psoriasis is an autoimmune condition affected the way doctors treated this condition.

A 1973 paper by John M. Moll and Verna Wright linked psoriasis to psoriatic arthritis. This was one of the first research papers to distinguish psoriatic arthritis from rheumatoid arthritis.

The understanding that psoriasis is an autoinflammatory condition rather than a skin disease has led to advances in treatment. In auto-inflammatory conditions, the immune system attacks healthy tissue and cells in the body.

Within the last decade, discoveries in genetics and molecular science have led to a greater understanding of how psoriasis affects people. Researchers now know that the cause is a complex interaction between immunological, environmental, cellular, and genetic factors.

One of the earliest treatments for psoriasis was coal tar. Medical professionals may still recommend using coal tar as a first-line treatment in cases of mild plaque psoriasis. And they may recommend it in combination with other medications for cases of moderate or severe plaque psoriasis.

In the 1920s, William Goeckerman developed Goeckerman therapy, which combined UVB light with coal tar to treat psoriasis. Doctors still use this treatment today for moderate or severe psoriasis.

Throughout the 1900s, experts created several new treatments, such as:

Biologic drugs are the most recent development in the treatment of psoriasis. These drugs interrupt the immune process of the condition, which can help ease its symptoms. A 2018 study reports that biologics are highly effective and lead to dramatic improvements in 8090% of people with psoriasis.

Healthcare professionals may also prescribe topical and oral retinoids, such as acitretin (Soriatane). Experts are also investigating the effectiveness of Janus kinase (JAK) inhibitors, which healthcare professionals already use in the treatment of rheumatoid arthritis and psoriatic arthritis.

People have been aware of psoriasis for centuries and often grouped this condition with leprosy (Hansens disease). Over time, experts began to recategorize this condition and learn more about how it affects the body, eventually discovering it is an autoimmune condition.

Similarly, treatment has evolved over time to become more effective. There are now several options that a doctor may recommend, many of which were first discovered in the 1900s.

Excerpt from:
The discovery and history of psoriasis: What to know - Medical News Today

Psoriasis can cause stress for someone with the condition due to difficulties managing symptoms, physical discomfort, or feelings of social embarrassment. Conversely, stress can also trigger psoriasis flares. Practicing self-care to improve mental health and reduce stress can help to reduce the chance of stress triggering further flares.

Psoriasis and stress share a symbiotic relationship of sorts, where each can cause and worsen the symptoms of the other.

Psoriasis is a type of immune-mediated disease where the immune system causes inflammation throughout the body.

While many people may associate the condition with scaly patches of skin, it can also cause issues in other areas of the body.

In addition, living with psoriasis can also affect a persons mental health. It may cause a person to feel stress relating to showing their skin, social situations, or caring for the condition.

Stress can then trigger a psoriasis flare or a worsening of symptoms. As a result, people living with psoriasis often benefit from managing both their physical and mental health.

Psoriasis can cause stress, and stress can cause psoriasis symptoms to worsen.

A 2018 review of studies looking at the link between psoriasis and stress notes that anywhere from 3188% of people living with psoriasis report stress as a trigger for their symptoms.

It also noted that, in addition to triggering flares, stress may also trigger the development of the condition itself in people predisposed to developing psoriasis.

How stress influences psoriasis is still not fully understood. According to an older study, one hypothesis, called the neurogenic inflammation hypothesis, states that psoriasis causes the release of neuropeptides, such as substance P (SP) and nerve growth factor (NGF).

These substances then cause local inflammation and result in the formation of psoriasis plaques. The hypothesis notes that stress releases high amounts of SP, which could then trigger the onset of the condition or flares.

When psoriasis plaques occur, it can cause stress for the person. The stress may relate to issues of embarrassment, the challenges of dealing with symptoms, discomfort, or a combination of different emotions.

The National Psoriasis Foundation recommends that all people living with psoriasis take steps to manage their stress as part of their treatment plan. They recommend a person:

According to a 2019 study, there is a link between alcohol intake and an increase in anxiety and depression. Therefore, a person may consider limiting their alcohol consumption to help minimize stress.

Before starting any new exercise programs, a person should talk with a doctor about what activities will be safe for them to perform.

Psoriasis is a lifelong condition characterized by periods of flares and remission. When treating psoriasis, a doctor will often suggest a combination of medications, therapies, mental health support, and lifestyle changes to help keep the condition under control.

Medical treatments may include:

Doctors may also recommend lifestyle changes that help manage symptoms and triggers. The American Academy of Dermatology Association (AAD) recommends a person take some steps to help manage their psoriasis at home:

In addition, a person should take measures to learn and avoid triggers. Triggers can vary from person to person but can include stress and weather changes.

By managing stress, a person may be able to help reduce psoriasis flares.

A person can consider the following general tips for managing stress, including:

Psoriasis triggers can vary from person to person. It is important for an individual to understand their triggers so that they can take steps to avoid them.

Some common triggers of psoriasis include:

Psoriasis and stress share a link both conditions can trigger the other.

Mental health treatment, including lifestyle changes such as physical exercise, can help prevent stress from triggering flares.

It can also help a person cope with the stress and other emotions that often accompany living with psoriasis.

See more here:
Psoriasis and stress: The relationship and how to break the cycle - Medical News Today

Health Policy and Law Daily

2022 JUN 02 (NewsRx) -- By a News Reporter-Staff News Editor at Health Policy and Law Daily -- Current study results on psoriatic arthritis have been published. According to news reporting out of Boston, Massachusetts, by NewsRx editors, research stated, Specialty medications provide effective treatment with limited adverse effects to patients with psoriasis and psoriatic arthritis; however, variable coverage and high costs often create a barrier to treatment for patients with commercial health insurance.

The news journalists obtained a quote from the research from Tufts Medical Center: We aimed to evaluate coverage of psoriasis and psoriatic arthritis specialty medications by commercial insurance companies. We compiled data regarding specialty drug coverage for psoriasis and psoriatic arthritis using Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database and analyzed the data for any notable trends. The SPEC database lists coverage decisions for 158 specialty drugs by 17 of the largest US commercial health plans, as well as data regarding the types of evidence cited by these insurance plans when making coverage decisions. Our results showed that insurance plans tend to be more restrictive than the U.S. Food and Drug Association (FDA) label when covering medications for psoriasis and psoriatic arthritis. Furthermore, medications for psoriatic arthritis tended to be less restricted than for psoriasis, and medications were most commonly approved as second line agents for both indications.

According to the news reporters, the research concluded: Our analysis confirms that variability in insurance coverage exists for the indications of psoriasis and psoriatic arthritis.

For more information on this research see: Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance Companies. Journal of Psoriasis and Psoriatic Arthritis, 2022. The publisher for Journal of Psoriasis and Psoriatic Arthritis is SAGE Publications.

A free version of this journal article is available at https://doi.org/10.1177/24755303221101843.

Our news editors report that additional information may be obtained by contacting Christine Learned, Department of Dermatology, Tufts Medical Center, Boston, MA, United States. Additional authors for this research include Sara Alsukait, Kristin R Fiumara, Melissa Ortega, James D Chambers, David Rosmarin.

ORCID is an identifier for authors and includes bibliographic information. The following is ORCID information for the author of this research: David Rosmarin (http://orcid.org/0000-0003-2786-0708).

(Our reports deliver fact-based news of research and discoveries from around the world.)

The rest is here:
Findings from Tufts Medical Center in Psoriatic Arthritis Reported (Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial...